Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb;25(2):e62-e63.
doi: 10.1016/S1473-3099(24)00811-9. Epub 2024 Dec 12.

Full 2023-24 season results of universal prophylaxis with nirsevimab in Galicia, Spain: the NIRSE-GAL study

Narmeen Mallah  1 , Jacobo Pardo-Seco  2 , Olaia Pérez-Martínez  3 , Carmen Durán-Parrondo  4 , Federico Martinón-Torres  5 ; NIRSE-GAL study group
Collaborators, Affiliations

Full 2023-24 season results of universal prophylaxis with nirsevimab in Galicia, Spain: the NIRSE-GAL study

Narmeen Mallah et al. Lancet Infect Dis. 2025 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

NM, JP-S and FM-T contributed equally. Members of the NIRSE-GAL study group are listed in the appendix (pp 1–2). JP-S and FM-T accessed and verified the underlying study data. All authors had access to the study data and approved the manuscript and are counted as responsible for its content. FM-T has acted as principal investigator in randomised controlled trials funded by Ablynx, Abbot, AstraZeneca, Seqirus, Sanofi Pasteur MSD, Sanofi Pasteur, Cubist, Wyeth, Merck, Pfizer, Roche, Regeneron, Jansen, Medimmune, Moderna, Novavax, Novartis, and GSK, with honoraria paid to his institution. FM-T reports consulting fees or advisory roles with GSK Vaccines SRL, Pfizer, Sanofi Pasteur, Janssen Pharmaceuticals, Moderna, MSD, and Seqirus. All other authors declare no competing interests. De-identified data will be made available upon reasonable request to the corresponding author (FM-T). This study was partially funded by Sanofi and AstraZeneca through a research grant to the Healthcare Research Institute of Santiago. This work was also supported by Framework Partnership Agreement between the Consellería de Sanidad de la Xunta de Galicia and GENVIP-IDIS-2021-2024 (SERGAS-IDIS March 2021; Spain), and Instituto de Salud Carlos III: TRINEO (PI22/00162), DIAVIR (DTS19/00049), Resvi-Omics (PI19/01039), ReSVinext (PI16/01569), Enterogen (PI19/01090), OMI-COVI-VAC (PI22/00406 to FM-T), and European Regional Development Fund (FEDER); Agencia Gallega de Inovación (GAIN): (IN607B 2020/08 and IN607A 2023/02), GEN-COVID (IN845D 2020/23 [to FM-T], IIN607A2021/05 [to FM-T]); Agencia Gallega de Conocimiento en Salud (ACIS): BI-BACVIR (PRIS-3), CovidPhy (SA 304 C); and Consorcio Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CB21/06/00103 [to FM-T]). This study was also supported by grants from the Galician Supercomputing Center, the Spanish Ministry of Science and Innovation, the Galician Government, and the European Regional Development Fund, the European Seventh Framework Programme for Research and Technological Development under the EUCLIDS project (grant agreement number 279185). The funders did not have any role in study design, data collection, analysis, interpretation, manuscript design and writing, or decision to submit the manuscript for publication.

LinkOut - more resources